Prelude Capital Management’s Sucampo Pharmaceuticals SCMP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-674,446
| Closed | -$12.1M | – | 1887 |
|
|
2017
Q4 | $12.1M | Buy |
674,446
+668,146
| +10,605% | +$8.23M | 0.97% | 15 |
|
|
2017
Q3 | $74K | Hold |
6,300
| – | – | 0.01% | 986 |
|
|
2017
Q2 | $66K | Sell |
6,300
-24,749
| -80% | -$252K | 0.01% | 910 |
|
|
2017
Q1 | $342K | Buy |
31,049
+19,649
| +172% | +$228K | 0.03% | 397 |
|
|
2016
Q4 | $154K | Sell |
11,400
-3,800
| -25% | -$53K | 0.02% | 676 |
|
|
2016
Q3 | $187K | Buy |
15,200
+3,239
| +27% | +$38.2K | 0.02% | 588 |
|
|
2016
Q2 | $131K | Buy |
11,961
+9,841
| +464% | +$110K | 0.02% | 650 |
|
|
2016
Q1 | $23K | Sell |
2,120
-8,980
| -81% | -$113K | ﹤0.01% | 1099 |
|
|
2015
Q4 | $192K | Buy |
11,100
+3,490
| +46% | +$62.6K | 0.03% | 590 |
|
|
2015
Q3 | $151K | Sell |
7,610
-14,490
| -66% | -$332K | 0.02% | 706 |
|
|
2015
Q2 | $363K | Sell |
22,100
-600
| -3% | -$10.4K | 0.05% | 391 |
|
|
2015
Q1 | $353K | Buy |
22,700
+3,900
| +21% | +$60.5K | 0.05% | 449 |
|
|
2014
Q4 | $268K | Sell |
18,800
-8,800
| -32% | -$92.9K | 0.04% | 537 |
|
|
2014
Q3 | $179K | Sell |
27,600
-8,300
| -23% | -$55.1K | 0.03% | 759 |
|
|
2014
Q2 | $248K | Buy |
35,900
+33,100
| +1,182% | +$234K | 0.03% | 660 |
|
|
2014
Q1 | $20K | Sell |
2,800
-7,068
| -72% | -$60.5K | ﹤0.01% | 1694 |
|
|
2013
Q4 | $93K | Buy |
+9,868
| New | +$70.4K | 0.02% | 866 |
|
Other funds holding SCMP
Prelude Capital Management's SCMP Position: Q1 2018 in Review
Prelude Capital Management sold out of Sucampo Pharmaceuticals (SCMP) in Q1 2018, closing a stake of 674,446 shares — an estimated $12.1M sold.
Prelude Capital Management first reported a position in SCMP in Q4 2013 and held it in 17 quarters. The position peaked at $12.1M in Q4 2017. 2 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.
- Prelude Capital Management reported no remaining Sucampo Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
- Prelude Capital Management sold 674,446 Sucampo Pharmaceuticals shares in Q1 2018, an estimated $12.1M.
- Prelude Capital Management first reported a position in Sucampo Pharmaceuticals in Q4 2013 and held it in 17 quarters.
- Prelude Capital Management's Sucampo Pharmaceuticals position peaked at $12.1M in Q4 2017.
- 2 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals as of Q1 2018.
Based on Prelude Capital Management's 13F filing for Q1 2018, filed 15 May 2018.